Clinical Rheumatology

, Volume 26, Issue 5, pp 811–813

Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab

  • Angel M. García Aparicio
  • José Rey Rey
  • Azucena Hernández Sanz
  • Juana Sampedro Alvarez
Case Report

DOI: 10.1007/s10067-006-0253-y

Cite this article as:
García Aparicio, A.M., Rey, J.R., Sanz, A.H. et al. Clin Rheumatol (2007) 26: 811. doi:10.1007/s10067-006-0253-y

Abstract

To date, hepatotoxicity with anti-TNF therapy has been associated with concomitant liver-toxicity drugs, infection or malignant diseases. We report the case of one patient with spondyloarthropathty who presented severe liver dysfunction related to infliximab. After the second infusion serum controls showed an slightly increase of transaminases. Before the administration of fifth infusion, infliximab therapy was stopped due to severe liver damage (AST 327 mU/ml, ALT 656 mU/mL, GGT 140 mU/mL, alkaline phosphate 227 mU/mL). Ten weeks after infliximab discontinuation serum concentrations of liver blood tests were normal but ankylosing spondylitis symptoms had relapsed. Therefore, he was treated with etanercept with a rapid and sustained improvement. Serum concentrations of albumin, AST, ALT, GGT and alkaline phosphate were followed and did not change for five months.

Keywords

EtanerceptHepatotoxicityInfliximab

Copyright information

© Clinical Rheumatology 2006

Authors and Affiliations

  • Angel M. García Aparicio
    • 1
  • José Rey Rey
    • 1
  • Azucena Hernández Sanz
    • 1
  • Juana Sampedro Alvarez
    • 1
  1. 1.Rheumatology UnitHospital Virgen de la SaludToledoSpain